abstract |
Provided are heterocyclic compounds as inhibitors of the KRAS G12C and uses thereof. Specifically, provided are the compounds of any of formula I to XI or stereoisomers, enantiomers, atropoisomerics or pharmaceutically acceptable salts thereof. Definition of each group in the formula can be found in the specification for details. |